Patient pathway

A China-specific treatment came up

A pathway for cross-border and country-specific drug conversations.

What this situation means

Some drugs or protocols may be country-specific, conditionally approved, or institution-specific.

Do not assume a China-approved medicine is available in the U.S., Korea, Japan, or EU.

Is this approved, trial-based, local protocol, compassionate access, or off-label?
How will response duration be monitored?

source-backed record

Approved in some places

source-backed record

Lived experience only

A trial record is a lead only. The trial team must confirm whether it fits.

Phase 1/2 · completed

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant advanced melanoma.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

Phase 3 · recruiting

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

Phase 1/2 · unknown

Supports the broader research concept of MEK inhibitor plus PD-1 inhibitor in melanoma, but not tunlametinib specifically.

Do not use this as evidence for tunlametinib plus nivolumab.

Phase 1 · unknown

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

lived experience only

A cohort-style thread for families to describe what happened, what they asked, and what they wish they had known. Not a recommendation thread.